
From the U.S. Code Online via GPO Access
[wais.access.gpo.gov]
[Laws in effect as of January 23, 2000]
[Document not affected by Public Laws enacted between
  January 23, 2000 and December 4, 2001]
[CITE: 42USC283a]

 
                 TITLE 42--THE PUBLIC HEALTH AND WELFARE
 
                    CHAPTER 6A--PUBLIC HEALTH SERVICE
 
              SUBCHAPTER III--NATIONAL RESEARCH INSTITUTES
 
                  Part A--National Institutes of Health
 
Sec. 283a. Establishment of program regarding DES


(a) In general

    The Director of NIH shall establish a program for the conduct and 
support of research and training, the dissemination of health 
information, and other programs with respect to the diagnosis and 
treatment of conditions associated with exposure to the drug 
diethylstilbestrol (in this section referred to as ``DES'').

(b) Education programs

    In carrying out subsection (a) of this section, the Director of NIH, 
after consultation with nonprofit private entities representing 
individuals who have been exposed to DES, shall conduct or support 
programs to educate health professionals and the public on the drug, 
including the importance of identifying and treating individuals who 
have been exposed to the drug.

(c) Longitudinal studies

    After consultation with the Office of Research on Women's Health, 
the Director of NIH, acting through the appropriate national research 
institutes, shall in carrying out subsection (a) of this section conduct 
or support one or more longitudinal studies to determine the incidence 
of the following diseases or disorders in the indicated populations and 
the relationship of DES to the diseases or disorders:
        (1) In the case of women to whom (on or after January 1, 1938) 
    DES was administered while the women were pregnant, the incidence of 
    all diseases and disorders (including breast cancer, gynecological 
    cancers, and impairments of the immune system, including autoimmune 
    disease).
        (2) In the case of women exposed to DES in utero, the incidence 
    of clear cell cancer (including recurrences), the long-term health 
    effects of such cancer, and the effects of treatments for such 
    cancer.
        (3) In the case of men and women exposed to DES in utero, the 
    incidence of all diseases and disorders (including impairments of 
    the reproductive and autoimmune systems).
        (4) In the case of children of men or women exposed to DES in 
    utero, the incidence of all diseases and disorders.

(d) Exposure to DES in utero

    For purposes of this section, an individual shall be considered to 
have been exposed to DES in utero if, during the pregnancy that resulted 
in the birth of such individual, DES was (on or after January 1, 1938) 
administered to the biological mother of the individual.

(e) Authorization of appropriations

    In addition to any other authorization of appropriations available 
for the purpose of carrying out this section, there are authorized to be 
appropriated for such purpose such sums as may be necessary for each of 
the fiscal years 1993 through 2003.

(July 1, 1944, ch. 373, title IV, Sec. 403A, as added Pub. L. 102-409, 
Sec. 2, Oct. 13, 1992, 106 Stat. 2092; amended Pub. L. 105-340, title I, 
Sec. 101(a), Oct. 31, 1998, 112 Stat. 3191.)


                               Amendments

    1998--Subsec. (e). Pub. L. 105-340 substituted ``2003'' for 
``1996''.

                  Section Referred to in Other Sections

    This section is referred to in section 300u-9 of this title.
